Skip to main content

Morning Overview

A study of 52,330 women found modern HRT users had no higher heart, stroke or clot rates

Women weighing menopause hormone therapy have long had heart-risk worries rooted in older research. A new Israeli analysis of 52,330 women, presented as a conference abstract, found that those who started modern hormone replacement therapy (HRT) did not have higher rates of heart attack, stroke, blood clots or early death than matched women who did not.

Read next on Morning Overview: Ocean mud suggests Cascadia and the San Andreas fault have broken within hours of each other

The finding is observational and preliminary, and the researchers themselves say it cannot prove cause and effect.

What the Clalit records show

Lead researcher Ronen Arbel of Clalit Health Services in Tel Aviv and Sapir College presented the work as abstract MDP0654 at the American Heart Association Scientific Sessions in Chicago, held Nov. 6 to 9. According to the AHA’s research release, issued under embargo until Nov. 2, the analysis used Clalit’s health records on women aged 45 to 59 with no history of heart disease, blood clots or cancer.

About half started hormone therapy, mostly oral or transdermal patch, and the other half had recently seen a gynecologist but never began it. The groups were matched on age, body mass index, blood pressure, cholesterol, diabetes, smoking and socioeconomic status. Records were reviewed for up to 23 years, with an average follow-up of 12 years. Epocrates, summarizing the abstract, reports 26,165 women in each group.

The release reports heart attack, stroke or related heart disease in 2,311 women in the hormone group (4.4%) and 2,383 women not on hormones (4.6%). Death before age 80 occurred in 659 (1.3%) and 653 (1.2%). Blood clots occurred in 174 and 175 women, which the release gives as 0.33% in both groups. Results were similar across oral, patch and gel forms.

Rates per person-year, and the confidence intervals

A fuller set of numbers appears in Healio’s report on the abstract, which gives rates per 1,000 person-years. Cardiovascular disease ran at 7.82 with hormone therapy and 7.99 without, an adjusted hazard ratio of 0.98 (95% confidence interval 0.93 to 1.04). Blood clots were 0.56 in both groups, hazard ratio 1.01 (0.82 to 1.24). Death before 80 was 2.13 versus 2.10, hazard ratio 1.03 (0.92 to 1.15). A composite of all three came to 10.05 in both groups.

Each interval spans 1.00, meaning the data do not separate the two groups. The intervals are not all narrow, though. The upper bound for blood clots is 1.24, and for death before 80 it is 1.15, so the analysis cannot rule out a modest increase in those outcomes.

The release’s percentages also differ in scale from the person-year rates. Dividing the reported counts by the full 52,330-woman cohort gives the quoted 4.4% and 4.6%, rather than dividing by each group’s 26,165 members, so the person-year comparison is the cleaner one.

Limits the researchers state

News-Medical quotes Arbel saying the therapies “do not appear to raise the risk of heart attack, stroke, clots or early death, even after long-term use.” Stacey E. Rosen, a physician and past AHA volunteer president who was not involved in the study, said the work “adds to growing evidence that today’s hormone therapy options may not increase the risk of heart disease,” according to the release.

The constraints are spelled out in the same release. The design is observational, so it cannot prove a direct link between hormone therapy and heart health. Exercise, diet, other conditions and symptom severity were not measured and may differ between groups. Women were grouped by the first type of hormone therapy used, and later changes were not tracked. Healio adds that women with established cardiovascular disease, prior blood clots or cancer were excluded, as were those who started therapy well after menopause, and that Arbel cautioned the results “should not be extrapolated beyond the population [they] studied.” The release also states that, as a conference abstract, the work is not peer-reviewed. The specific products, doses and durations of use are not reported in the coverage.

The older evidence and the label change

The release explains that earlier randomized trials produced mixed results and relied largely on older, higher-dose formulations started long after menopause. Arbel told Healio that this evidence, from the Women’s Health Initiative era, led many physicians and patients to abandon hormone therapy, and that the trials that shaped practice used formulations now largely obsolete.

The AHA’s newsroom page notes that the FDA removed boxed warnings from hormone therapy products in November 2025, a decision it says rested on a review concluding hormone therapy is not associated with increased cardiovascular disease, breast cancer or dementia risk. The American College of Obstetricians and Gynecologists, per the same page, recommends starting therapy within 10 years of menopause onset and before age 60.

Arbel’s position, as relayed by Healio, is that hormone therapy should be prescribed for menopausal symptoms and not as cardiovascular prevention. The open question is whether a peer-reviewed paper, with its full methods, funding and disclosures, will match the abstract. The release says co-authors, disclosures and funding appear in the abstract itself.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.


More from Morning Overview

Morning Overview is reader-supported. Some links in our articles are affiliate links, and we may earn a commission at no extra cost to you. As an Amazon Associate I earn from qualifying purchases. Full disclosure.